The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists.
| Autor: | Fang H; School of Environmental and Chemical Engineering, Shanghai University, China., Niu B; School of Life Sciences, Shanghai University, China., Chen Q; School of Environmental and Chemical Engineering, Shanghai University, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current medicinal chemistry [Curr Med Chem] 2024; Vol. 31 (20), pp. 2921-2943. |
| DOI: | 10.2174/0929867330666230416153301 |
| Abstrakt: | Diabetes mellitus has become a serious life-threatening disease. As one of the new drugs for the treatment of diabetes, GLP-1 receptor agonists have attracted a lot of attention. Compared with traditional hypoglycemic drugs, GLP-1 receptor agonists have good safety and tolerability. To a certain extent, they overcome the problem of the short half-life of natural GLP-1 in vivo and can exist stably in patients for a long time, achieving good results in the treatment of diabetes, as well as improving the symptoms of some complications. The GLP-1 receptor agonists in the market are all peptide drugs. Compared with peptide drugs, small molecule agonists have the advantages of low cost and oral administration. In this article, we review the recent research progress of GLP-1 receptor agonists. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|